E.A. LATYSHEVA, T.V. LATYSHEVA, I.A. MARTYNOVA

NRC Institute of Immunology FMBA of Russia, 24 Kashirskoye shosse, Moscow, Russian Federation, 115478

Latysheva E.A. ― Cand. Med. Sc., Associate Professor, researcher, tel. (499) 612-77-73

Latysheva T.V. ― D. Med. Sc., Professor, Head of the Department of Immunopathology of Adults and the Department of Reanimation and Intense Therapy, tel. (499) 617-80-85, e-mail: [email protected]

Martynova I.A. ―

Replacement immunotherapy with intravenous immunoglobulin (IVIG) has been used successfully for the treatment of primary immunodeficiency (PID) for over 60 years. During this time, a huge step forward was made in purification and manufacturing methods. In addition, IVIG therapy has been approved for a huge number of other diseases and this number is steadily expanding causing an appearance of new IVIG on the pharmaceutical market. These drugs vary in composition, manufacturing technology and, as a consequence, in safety, administration rate, and efficacy. The new IVIG was recently introduced on the Russian market ― IG Vena. It has already proved its safety and efficacy abroad. The article presents the experience of using IG Vena in adults with PID at the Immunopathology Department of the Institute of Immunology FMBA Russia.

Key words: primary immunodeficiency, replacement immunotherapy, intravenous immunoglobulins.